7
Participants
Start Date
May 31, 2012
Primary Completion Date
March 31, 2016
Study Completion Date
March 31, 2016
Rnalozine
. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
University of New Mexico Health Science Center, Albuquerque
Collaborators (1)
Gilead Sciences
INDUSTRY
University of New Mexico
OTHER